Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Working Capital Changes (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Other Working Capital Changes for 6 consecutive years, with -$20000.0 as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 125.97% to -$20000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$142000.0 through Dec 2025, down 133.02% year-over-year, with the annual reading at -$142000.0 for FY2025, 133.02% down from the prior year.
  • Other Working Capital Changes hit -$20000.0 in Q4 2025 for Insight Molecular Diagnostics, up from -$57000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $1.1 million in Q1 2021 to a low of -$1.0 million in Q2 2021.
  • Historically, Other Working Capital Changes has averaged -$8100.0 across 5 years, with a median of -$31500.0 in 2023.
  • Biggest YoY gain for Other Working Capital Changes was 1245.0% in 2023; the steepest drop was 3460.0% in 2023.
  • Year by year, Other Working Capital Changes stood at -$1.0 million in 2021, then surged by 103.94% to $40000.0 in 2022, then surged by 1245.0% to $538000.0 in 2023, then plummeted by 85.69% to $77000.0 in 2024, then plummeted by 125.97% to -$20000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for IMDX at -$20000.0 in Q4 2025, -$57000.0 in Q3 2025, and -$35000.0 in Q2 2025.